Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
An acute leukemia of ambiguous lineage characterized by blasts which coexpress myeloid and T or B lineage antigens or concurrent B and T lineage antigens. (WHO, 2001)
Biomarker and diagnostic research for acute biphenotypic leukemia has been reported in the published literature.
16 clinical trials registered, 6 recruiting. Interventions under study include drug therapy, other interventions, procedural interventions, and biologic therapy. Pipeline includes 8 PHASE2, 6 PHASE1, 2 NA. Research is sponsored by a mix of industry and academic institutions.
NCT ID | Title | Phase | Sponsor | Status |
|---|---|---|---|---|
[NCT02727803](https://clinicaltrials.gov/study/NCT02727803) |
Data assembled from 4 of 12 sources · Last updated Oct 3, 2026, 12:21 PM UTC
European rare disease database
Common questions about acute biphenotypic leukemia
Personalized NK Cell Therapy in CBT |
PHASE2 |
M.D. Anderson Cancer Center |
RECRUITING |
[NCT03326921](https://clinicaltrials.gov/study/NCT03326921) | HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant | PHASE1 | Fred Hutchinson Cancer Center | RECRUITING |
[NCT04047641](https://clinicaltrials.gov/study/NCT04047641) | Cladribine, Idarubicin, Cytarabine, and Quizartinib in Treating Patients With Newly Diagnosed, Relapsed, or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome | PHASE1 | M.D. Anderson Cancer Center | RECRUITING |
[NCT02115295](https://clinicaltrials.gov/study/NCT02115295) | Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid Leukemia | PHASE2 | M.D. Anderson Cancer Center | RECRUITING |
[NCT05794880](https://clinicaltrials.gov/study/NCT05794880) | MCW Alpha/Beta T-Cell and B-Cell Depletion With Targeted ATG Dosing | NA | Medical College of Wisconsin | RECRUITING |
46 publications have been identified in PubMed for acute biphenotypic leukemia. Research spans Case Report / Case Series (24%), Basic Science / Preclinical (17%), and Diagnostic / Biomarker (15%).
Research Type | Count | % of Total |
|---|---|---|
Patient case studies | 11 | 24% |
Laboratory research | 8 | 17% |
Testing and diagnosis research | 7 | 15% |
Clinical study results | 6 | 13% |
Disease patterns and progression | 6 | 13% |
Research summaries | 4 | 9% |
New treatment approaches | 4 | 9% |
Shaforostova I (2026). [PMID: 42192954](https://pubmed.ncbi.nlm.nih.gov/42192954/). *Cancers (Basel)*. [Epidemiology / Natural History]
Shome A (2026). [PMID: 42147558](https://pubmed.ncbi.nlm.nih.gov/42147558/). *Cureus*. [Epidemiology / Natural History]
Haider MZ (2026). [PMID: 32809524](https://pubmed.ncbi.nlm.nih.gov/32809524/). *Unknown Journal*. [Basic Science / Preclinical]
Zaucha JM (2026). [PMID: 42193279](https://pubmed.ncbi.nlm.nih.gov/42193279/). *Biomedicines*. [Review / Meta-Analysis]
Erbella F (2026). [PMID: 41124667](https://pubmed.ncbi.nlm.nih.gov/41124667/). *Blood advances*. [Clinical Trial Publication]
Mimura K (2026). [PMID: 41790573](https://pubmed.ncbi.nlm.nih.gov/41790573/). *Blood*. [Basic Science / Preclinical]
Arreola RMG (2026). [PMID: 41561684](https://pubmed.ncbi.nlm.nih.gov/41561684/). *EJHaem*. [Epidemiology / Natural History]
Galán-Gómez V (2025). [PMID: 40176077](https://pubmed.ncbi.nlm.nih.gov/40176077/). *Experimental hematology & oncology*. [Clinical Trial Publication]
Katlinskaya Y (2025). [PMID: 40515477](https://pubmed.ncbi.nlm.nih.gov/40515477/). *The oncologist*. [Diagnostic / Biomarker]
Tachibana M (2025). [PMID: 41258689](https://pubmed.ncbi.nlm.nih.gov/41258689/). *Clinical and translational science*. [Clinical Trial Publication]